Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.

@article{Bron1991MultipledoseEC,
  title={Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927.},
  author={A. Bron and E. Lippa and F. Gunning and C. B{\'e}nichou and P. Lesure and D. Sirbat and J. Royer and J. Flament and C. Clineschmidt and D. Panebianco},
  journal={Archives of ophthalmology},
  year={1991},
  volume={109 1},
  pages={
          50-3
        }
}
The multiple-dose twice-daily efficacy of the topical carbonic anhydrase inhibitor MK-927, a racemic compound, was compared with that of its pharmacologically more active S-enantiomer in a four-center, double-masked, randomized, placebo-controlled, parallel study of 1.8% sezolamide hydrochloride (MK-417), 2% MK-927, and placebo, given twice daily to 48 patients with bilateral primary open angle glaucoma or ocular hypertension and morning intraocular pressure greater than 24 mm Hg in both eyes… Expand
Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: A multiple-dose efficacy study
Topically active carbonic anhydrase inhibitors for glaucoma.
Dorzolamide: A Review
Pharmacological Advances in the Treatment of Glaucoma
...
1
2
...

References

SHOWING 1-10 OF 11 REFERENCES
MK-927: a topically effective carbonic anhydrase inhibitor in patients.
Thienothiopyran-2-sulfonamides: a novel class of water-soluble carbonic anhydrase inhibitors.
Evidence of a high-activity C type of carbonic anhydrase in human ciliary processes.
...
1
2
...